AstraZeneca is selling three older drugs for asthma and rhinitis for at least $350 million as the company continues a strategy of divesting assets and investing in its pipeline of new medicines.
from Reuters: Company News https://ift.tt/2ySPW4g
via IFTTT
from Reuters: Company News https://ift.tt/2ySPW4g
via IFTTT
Post a Comment